Benzonatate polacrilex

Drug Profile

Benzonatate polacrilex

Latest Information Update: 16 Sep 2014

Price : $50

At a glance

  • Originator Alitair Pharmaceuticals Inc
  • Class Aminobenzoic acids; Antitussives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cough

Highest Development Phases

  • Research Cough

Most Recent Events

  • 16 Sep 2014 Benzonatate polacrilex is available for licensing as of 16 Sep 2014. http://www.alitair.com/
  • 16 Sep 2014 Early research in Cough in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top